The list of the original drugs includes highly effective neurothropic, cardiovascular, antihystaminic (antiallergic), antibacterial, antiviral, antitumor and other preparations.

Neurotropic drugs include:

• For the first time, there has been created at the Institute, family of tetracyclic antidepressants with a new mechanism of action - the reversible monoaminooxydase (MAO) inhibitors. This family represents a new heterocyclic system - derivatives of pyrazino-carbazole and pyrazino-carboline and contains such drugs as pirlindole, metralindole and tetrindole;
• Tricyclic antidepressant from a new chemical class (a derivative of 3,4-diazaphenoxazine) - pipofezine, combines an anti-depressive effect with a sedative activity and is deprived of anticholinergic properties.
• Peripheral and central anticholinergic and cholinomimetic drugs, including anticholinergic alkaloid platyphylline, synthetic anticholinergics metacine and aprofene; highly effective bronchodilatator drug troventol (truvent); central anticholinergic and antiparkinsonic drug tropacine (dipheniltropin hydrochloride); ganglioblocker dimecoline, cholinomimetic drug aceclidine, anticholineesterase alkaloid galanthamine (attracting now attention as a drug for treatment of Alzheimer's disease) etc.
• Psychostimulators mesocard and feprosidine.
• Miorelaxants diplacine and qualidile;
• Synthetic analgesics trimeperidine and dimenoxadole.

• Class III antiarrhythmic drug nibentane, created as a result of extensive studies of a large group of derivatives of diaminoalkanes;
• new by its structure and action, the hybrid alpha- and beta-blocker proxodolole, having high antihypertensive antiischemic and antiglaucomal activity;
• highly effective alpha-blocker tropodifene;
• antihypertensive and sedative drug benzochlidene.

Original H1-antihystaminic preparations include quibenadine and sequifenadine. Both of these have high antiallergic activity and are deprived of the central depressive (sedative) effect. These drugs, as well as the cholinomimetic aceclidine and antihypertensive drug benzalidine, were created in the Institute as a result of synthesis and study of a large group of quinoclidine derivatives.

The results of a search for a new antibacterial preparations were:

• Creation of a new group of antibacterial drugs - derivatives of quinoxaline chinoxydine and dioxydine, which are highly effective against gram positive and gram negative aerobic bacteria. They are also effective against micobacteria  tuberculosis according to the latest studies.
• Creation of original combined sulphanilamide drug sulfatone, similar by its efficiency with co-trimexazole.
• Creation of a number antituberculesis drugs, hydrazine derivatives of isonicotinic acid: ftivazid, saluside, saluside soluble, methazid etc.

The Institute launched a number of antitumor drugs, including original derivatives of a dispirotripiperasinium (prospidin, spirobromine etc) and ethylenimine (dipin, pumitepa and fotretamine).

Several other preparations important for medical practice were also created at the Institute: emoxipinum - antihypoxante and antioxydante, mexamine - radioprotective drug, leukogene - leukopoese stimulator etc.

Search for new drugs in various classes of organic compounds is now in progress at the Center for Drug Chemistry. Thus, the Institute is carrying out a search for:

• class III antiarrhythmics;
• antibacterial compounds among the quinolonecarboxylic acid derivatives;
• substances with antiviral and immunomodulatory activity among analogues of arbidole;
• antituberculesis drugs with new mechanism of action;
• antifungal drugs.